Remission and recovery in lurasidone-treated patients with bipolar depression: post-hoc analysis of a 6-week, placebo-controlled trial followed by a 6-month extension

被引：0
|
作者：
Loebel, A. [1 ]
Siu, C. [2 ]
Rajagopalan, K. [3 ]
Pikalov, A. [4 ]
Cucchiaro, J. [5 ]
Ketter, T. [6 ]
机构：
[1] Sunovion Pharmaceut Inc, Ft Lee, NJ USA
[2] COS Consulting, Data Sci & Analyt, Montreal, PQ, Canada
[3] Sunovion Pharmaceut Inc, Hlth Econ & Outcomes Res, Marlborough, MA USA
[4] Sunovion Pharmaceut Inc, Clin Dev & Med Affairs, Ft Lee, NJ USA
[5] Sunovion Pharmaceut Inc, Clin Operat, Ft Lee, NJ USA
[6] Stanford Univ, Psychiat & Behav Sci, Stanford, CA 94305 USA
来源：
BIPOLAR DISORDERS | 2015年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [21] Lurasidone monotherapy in the treatment of bipolar I depression: Efficacy Results of a randomized, double-blind, placebo-controlled, 6-week elevate study
    Kato, T.
    Ishigooka, J.
    Masuda, T.
    Watabe, K.
    Fujimori, T.
    Higuchi, T.
    BIPOLAR DISORDERS, 2019, 21 : 131 - 131
  • [22] The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: A pooled post-hoc analysis of two randomized, placebo-controlled trials
    Kato, Masaki
    Masuda, Takahiro
    Sano, Fumiya
    Kato, Tadafumi
    JOURNAL OF AFFECTIVE DISORDERS, 2023, 337 : 150 - 158
  • [23] Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia
    Marder, Stephen R.
    Eriksson, Hans
    Zhao, Yudong
    Hobart, Mary
    ACTA NEUROPSYCHIATRICA, 2020, 32 (03): : 153 - 158
  • [24] LURASIDONE IN THE TREATMENT OF ACUTE SCHIZOPHRENIA: RESULTS OF THE DOUBLE-BLIND, PLACEBO-CONTROLLED, 6-WEEK, PEARL 3 TRIAL
    Loebel, Antony
    Cucchiaro, Josephine
    Sarma, K.
    Hsu, J.
    Kalali, A. H.
    Potkin, S. G.
    SCHIZOPHRENIA BULLETIN, 2011, 37 : 313 - 313
  • [25] Lurasidone monotherapy in the treatment of bipolar I depression: Safety and tolerability Results of a randomized, double-blind, placebo-controlled, 6-week elevate study
    Kato, T.
    Ishigooka, J.
    Masuda, T.
    Watabe, K.
    Fujimori, T.
    Higuchi, T.
    BIPOLAR DISORDERS, 2019, 21 : 131 - 131
  • [26] Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: Post Hoc Analysis of a Randomized Placebo-Controlled Trial
    Singh, Manpreet K.
    Pikalov, Andrei
    Siu, Cynthia
    Tocco, Michael
    Loebel, Antony
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2020, 30 (10) : 590 - 598
  • [27] LURASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR DEPRESSION ASSOCIATED WITH MIXED (SUBSYNDROMAL HYPOMANIC) FEATURES: POST HOC ANALYSIS OF A RANDOMIZED PLACEBO-CONTROLLED TRIAL
    Pikalov, Andrei A.
    Siu, Cynthia
    Tocco, Michael
    Loebel, Antony
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2017, 56 (10): : S169 - S169
  • [28] Lurasidone in Post-Menopausal Females with Major Depressive Disorder with Mixed Features: Post-Hoc Analysis of a Placebo-Controlled Trial
    Sramek, John
    Loebel, Anthony
    Murphy, Michael
    Mao, Yongcai
    Pikalov, Andrei
    Cutler, Neal
    BIOLOGICAL PSYCHIATRY, 2017, 81 (10) : S275 - S275
  • [29] Lurasidone in post-menopausal females with major depressive disorder with mixed features: Post-hoc analysis of a placebo-controlled trial
    Sramek, John
    Loebel, Antony
    Murphy, Michael
    Mao, Yongcai
    Pikalov, Andrei
    Cutler, Neal R.
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2017, 78 : 12 - 17
  • [30] THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY
    Goldman, Robert S.
    Findling, Robert L.
    Silva, Robert M.
    Cucchiaro, Josephine B.
    Deng, Ling
    Loebel, Antony
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2016, 55 (10): : S163 - S164
12345